About Selventa
Selventa is a Healthcare company based in Cambridge (United States) founded in 2001. Selventa specializes in diagnostics for personalized medicine, advancing tailored healthcare solutions. It operates on a B2B model. Selventa has raised $11.96 million across 3 funding rounds from investors including Flagship Pioneering and Pappas Capital. Its focus areas include Biotechnology, Diagnostics and Personalized Medicine. Its legal entity is Selventa Inc. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Selventa, based in Cambridge, focuses on providing healthcare solutions, advancing biotech innovations, offering diagnostic solutions, and personalized medicine. Selventa specializes in diagnostics for personalized medicine, advancing tailored healthcare solutions. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
- Headquarters Cambridge, United States
- SectorsHealthcare
- Website selventa.com
- Social X
- Legal Name Selventa Inc
- Total Equity Funding$11.96M (USD)
in 3 rounds
- Latest Funding Round$4.96M (USD), Series A
Nov 2011
- InvestorsFlagship Pioneering
& 1 more
Funding Insights of Selventa
Selventa has successfully raised a total of $11.96M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.96 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.96M
- Total Rounds 3
- Last Round Series A — $4.96M
- First Round $6.5M
(Sep 2003)
- Investors Count 2
All 3 funding rounds of Selventa with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2011 | $4.96M | Series A | – | – | – |
| May 2010 | $500,000 | Series A | – | – | – |
| Sep 2003 | $6.5M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Selventa
Selventa has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Flagship Pioneering and Pappas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States |
Investor details for Selventa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Selventa
3 dated milestones of Selventa across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Selventa is founded.
- Funding First funding round of $6.5M.
- Funding Latest funding round, Series A, of $5.0M.
Competitors of Selventa
Selventa has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Selventa
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical Genomics
3 companies that operate in the same segment as Selventa (Clinical Genomics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Selventa
Complete news archive for Selventa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selventa
Selventa was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Selventa is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Selventa is a funded company, having raised a total of $11.96M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.5M, raised on Sep 2003.
Selventa, based in Cambridge, focuses on providing healthcare solutions, advancing biotech innovations, offering diagnostic solutions, and personalized medicine. Selventa specializes in diagnostics for personalized medicine, advancing tailored healthcare solutions. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
Selventa's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Selventa has 2 investors. Key investors include Flagship Pioneering, and Pappas Capital.
Selventa operates through Selventa Inc.